One proprietary gene therapy platform.
Three life-changing treatments.
Innervate is advancing the targeted delivery of β-GDNF gene therapy to restore function in some of the most devastating neurodegenerative conditions — built on pioneering expertise in treating the central nervous system.
Harnessing GDNF’s restorative power for the central nervous system
Innervate Tx Ltd is focused on the targeted delivery of GDNF gene therapy to treat Motor Neuron Disease, Spinal Cord Injury and Parkinson’s Disease — exploiting our management team’s unique and pioneering expertise in neurodegenerative conditions.
A proprietary β-GDNF isoform
We harness GDNF’s restorative properties using a proprietary isoform designed for regulated, long-term expression in the CNS.
Superior delivery technology
Our delivery technology places therapy precisely where it is needed, achieving an effective dose that systemic routes cannot reach.
One platform, many targets
Combining the β-GDNF isoform with our delivery technology creates a single Gene Therapy Platform able to target numerous CNS-based disorders.
A single platform engineered for the brain
Translating the neuroprotective and neurorestorative effects of GDNF from pre-clinical models into the clinic has long been the central challenge. Innervate’s platform is built to meet it — four capabilities working as one.
Effective & safe vector
An AAV5 vector with a strong CBA promoter — high transduction of neurons and glia, good CNS distribution, and a low prevalence of neutralising antibodies.
Single administration
An effective delivery strategy that treats the target in a single administration, using axonally transported vectors and convection-enhanced delivery.
Long-term expression
Regulated, durable GDNF expression and release — sustaining the restorative signal where degeneration occurs.
Scalable delivery
A scalable approach that allows rapid deployment and commercialisation across multiple CNS indications.
CBA is a strong constitutive promoter driving long-term expression in neurons, glia and muscle. AAV5 has an established safety record in clinical CNS studies.

A single molecule that protects and restores neurons
GDNF is a neurotrophic factor for dopaminergic, serotonergic, noradrenergic, cholinergic and motor neurons — the very cells lost across the conditions we target. In pre-clinical models it improves motor function in Parkinson’s, ALS and spinal cord injury.
- Neuroprotective and neurorestorative across multiple neuron types
- Promotes glial cells that give metabolic support and reduce inflammation
- Restores motor function when delivered to the right target in pre-clinical models
GDNF acts on the neurons that degenerate in disease
Rigidity, bradykinesia, postural instability and tremor in Parkinson’s.
Mood, sleep and cognition — the non-motor burden of disease.
Gait, fatigue, executive function and autonomic control.
Attention, memory and postural stability.
Voluntary movement — the cells lost in MND/ALS.
Metabolic support, myelination and inflammation control.
Precision delivery, designed as a day case
Effective dose cannot be reached through systemic or intra-CSF routes. Innervate delivers therapy directly into CNS tissue using the Neurochase drug delivery system — precise, low-pressure and homogeneous, with distribution that systemic routes cannot match.

Safe
A low-profile, flexible cannula with skull fixation enables rapid insertion (under 10 minutes each). Pre-filled dispensers are connected on the ward, away from theatre, allowing infusions with neurological and MRI monitoring.
Effective
A novel cannula gives precise, low-pressure, homogeneous dosing with highly effective reflux control (Vd/Vi = 4.5:1). Multiple disease-specific volumes can be treated simultaneously.
Scalable
Semi-automated pre-surgical planning and a simplified workflow separate cannula insertion from infusion, making efficient use of theatre and staff with no loss of valuable therapy.
The patient pathway
Planning MRI
Outpatient scan generates the surgical plan.
Day-case surgery
Plan registered to patient; cannula inserted under GA or LA.
Awake infusions
Simultaneous infusions monitored with neuro observations.
Cannula removal
Removed simply at the bedside.
Discharge
Same or next-day discharge home.
Three programmes, one platform
Each programme applies the same GDNF platform to a different target in the central nervous system — addressing conditions with profound unmet need.

Motor Neuron Disease (MND/ALS)
GDNF protects and restores the neurons and supporting cells that degenerate in MND/ALS. Motor-cortex delivery carries the therapy via axonal transport to secondary motor neurons in the brainstem and spinal cord.
Lead programme — first-in-man studies planned at Hospitals in the UK. Explore programme →
Parkinson’s Disease (PD)
Beyond dopamine, Parkinson’s involves the loss of serotonergic, noradrenergic and cholinergic neurons. GDNF is neuroprotective and neurorestorative across all of them; delivery to the striatum is associated with recovery of motor function.
Targeted striatal delivery addressing motor and non-motor symptoms. Explore programme →
Spinal Cord Injury (SCI)
GDNF reduces secondary injury after SCI, promotes axonal growth and regeneration, increases blood supply and reduces lesion size. Innervate delivers to the pons, with axonal transport to primary and secondary motor neurons and sensory pathways.
Pons delivery driving functional recovery after injury. Explore programme →